Important Notice for Soleno Therapeutics Investors: Class Action Lawsuit Deadline Approaches

Attention Soleno Therapeutics Investors!

Kahn Swick & Foti, LLC (KSF), along with its partner Charles C. Foti, Jr., former Attorney General of Louisiana, has issued a critical notice to investors in Soleno Therapeutics, Inc. regarding a class action lawsuit. Investors should be aware of the impending application deadline of May 5, 2026, for filing in connection with alleged securities fraud.

What You Need to Know

The class action seeks to represent investors negatively impacted by alleged fraudulent practices between March 26, 2025, and November 4, 2025. During this period, it is claimed that Soleno and certain executives failed to disclose important information affecting investors, specifically regarding its flagship product, DCCR, designed for treating hyperphagia associated with Prader-Willi syndrome (PWS).

Allegations

The lawsuit points to several significant oversights:
1. Misrepresentation of Clinical Trials: The Phase 3 clinical trials for DCCR reportedly did not adequately disclose important safety concerns, including excessive fluid retention observed in patients, which are critical for evaluating the drug's viability.
2. Underreported Risks: Due to the alleged misinformation, the company has been accused of downplaying the unique safety risks linked to DCCR administration.
3. Impact on Commercial Viability: The potential adverse events, such as higher patient discontinuation rates and negative regulatory responses, were not fully disclosed, leading to heightened risks that were never communicated to investors.

The case has been filed under the caption City of Pontiac Police and Fire Retirement System v. Soleno Therapeutics, Inc., No. 26-cv-01979. This lawsuit aims to recover losses for investors who can prove that they sustained losses as a result of these alleged actions.

Next Steps for Affected Investors

If you invested in Soleno Therapeutics during the specified time frame and experienced a financial setback, you must act quickly. Reaching out to KSF is crucial as they can guide you through the process of becoming a lead plaintiff, which can enhance your chances of recovering losses. However, remember that participating in the lawsuit does not necessitate serving as a lead plaintiff to qualify for potential recoveries.

To contact KSF, investors can reach out to Lewis Kahn, Managing Partner, via:

- Phone: 1-877-515-1850
- Email: email protected]
- Website: [Kahn Swick & Foti Cases

About Kahn Swick & Foti, LLC

KSF is recognized as one of the top boutique law firms specializing in securities litigation. Over the past year, they have been ranked among the top 10 firms in the nation based on settlement value, showcasing their effectiveness in representing both institutional and retail investors who have suffered losses due to corporate malfeasance. With offices in major U.S. cities, KSF brings significant expertise and advocacy for clients navigating securities-related legal challenges.

In a landscape where investors' rights are constantly under pressure, KSF's commitment to recovering losses for their clients remains steadfast. Their history of successful litigations speaks volumes, making them a reliable entity for those affected by corporate misconduct.

Investors are strongly encouraged to take action before the May deadline to substantially increase their chances of receiving due compensation and ensure their voices are heard in this essential legal procedure.